Analyst Ratings January 29, 2026

Morgan Stanley lifts IBM price target to $304 after strong FCF; rating remains Equalweight

Analysts across the street raise targets following a better-than-expected quarter and healthy free cash flow, while software and consulting trends stay mixed

By Derek Hwang IBM
Morgan Stanley lifts IBM price target to $304 after strong FCF; rating remains Equalweight
IBM

Morgan Stanley raised its price target on IBM to $304 from $252 while keeping an Equalweight rating, citing stronger-than-expected free cash flow in 2025 and fourth-quarter outperformance driven by Enterprise License Agreement renewals and mainframe strength. IBM reported EPS of $4.52 and revenue of $19.7 billion for Q4 2025, beating consensus, and other brokerages including Evercore ISI and BMO Capital increased their targets as well.

Key Points

  • Morgan Stanley raised its IBM price target to $304 from $252 but kept an Equalweight rating, citing improved free cash flow in 2025.
  • IBM reported Q4 2025 results above expectations - EPS of $4.52 versus $4.29 expected, and revenue of $19.7 billion versus $19.22 billion forecast.
  • Other brokerages, including Evercore ISI and BMO Capital, also raised targets after the quarter, reflecting broad-based sales growth and strong free cash flow, while noting mixed trends in software and consulting.

Morgan Stanley increased its 12-month price objective on IBM (NYSE:IBM) to $304.00 from $252.00, while retaining an Equalweight recommendation on the shares. At the time of the note, IBM was trading at $294.16 and carried a price-to-earnings ratio of 35.23, a multiple InvestingPro characterizes as high relative to near-term growth prospects.

The firm's adjustment to its valuation was driven primarily by IBM's free cash flow (FCF) performance in 2025. The company generated $14.7 billion of FCF for the year, ahead of management's initial guidance of $13.5 billion. On a levered basis, IBM's trailing twelve-month free cash flow totaled $12.47 billion, which equates to a 5% free cash flow yield.

Morgan Stanley analyst Erik Woodring highlighted several operational drivers that supported the stronger quarter. He pointed to Enterprise License Agreement (ELA) renewals and incremental upside in mainframe results as contributors to the technology company's fourth-quarter outperformance.

The research note outlined that software and consulting revenue trends remain uneven, and Morgan Stanley said IBM's outlook for 2026 appears skewed toward the back half of the year. Despite the notable increase to the price target, the firm chose not to raise its rating above Equalweight, citing the improved free cash flow as the key input for the revised valuation rather than a change in near-term growth visibility.

IBM's December quarter results were broadly positive versus consensus. The company reported adjusted earnings per share of $4.52, beating the expected $4.29, and posted revenue of $19.7 billion against forecasts of $19.22 billion.

Other brokerages reacted to the quarterly beats with their own target revisions. Evercore ISI increased its price target to $345 from $330 and maintained an Outperform rating, citing the company's better-than-expected December quarter and noting broad-based growth across IBM's segments, with overall sales up 12% in the period. BMO Capital also raised its target, taking it to $350 from $305 while keeping a Market Perform rating; the firm described the quarter as reasonable, noting some softness in Red Hat and Consulting offset by strength in Data and strong free cash flow.

Collectively, these analyst moves reflect a reassessment of IBM's near-term cash generation and quarterly execution. At the same time, firms that upgraded targets did not uniformly change their ratings to stronger stances, underscoring continued caution around uneven software and consulting momentum and the company-specific timing of 2026 growth.


Disclosure:

Risks

  • Software and consulting revenue trends remain mixed - continued weakness in these segments could weigh on growth and analyst outlooks.
  • IBM's 2026 performance is expected to be weighted toward the second half of the year - a delayed recovery could pressure near-term investor sentiment and valuations.
  • Some segments showed softness, specifically Red Hat and Consulting as noted by BMO Capital - concentration of underperformance in key business lines could offset gains in Data and free cash flow.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026